SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 34, Issue 15, 2016, Pages 1723-1731

  Van Hazel, Guy A ^a   Heinemann, Volker ^l   Sharma, Navesh K ^o   Findlay, Michael P N ^r   Ricke, Jens ^m   Peeters, Marc ^v   Perez, David ^s   Robinson, Bridget A ^t   Strickland, Andrew H ^e   Ferguson, Tom ^b   Rodríguez, Javier ^w   Kröning, Hendrik ⁿ   Wolf, Ido ^x   Ganju, Vinod ^f   Walpole, Euan ^h   Boucher, Eveline ^z   Tichler, Thomas ^y   Shacham Shmueli, Einat ^x   Powell, Alex ^d   Eliadis, Paul ⁱ   Isaacs, Richard ^u   Price, David ^c   Moeslein, Fred ^p   Taieb, Julien ^aa   Bower, Geoff ^c   Gebski, Val ^j   Van Buskirk, Mark ^q   Cade, David N ^k   Thurston, Kenneth ^k   Gibbs, Peter ^g   more..

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c Mount Medical Center   (Australia)

^d HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^e MONASH MEDICAL CENTRE   (Australia)

^f Radiology Department   (Australia)

^g WESTERN HOSPITAL   (Australia)

^h PRINCESS ALEXANDRA HOSPITAL   (Australia)

ⁱ WESLEY HOSPITAL   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

^k Sirtex Medical Limited   (Australia)

^l UNIVERSITY OF MUNICH   (Germany)

^m University Clinic Magdeburg   (Australia)

ⁿ Schwerpunktpraxis of Haematology and Oncology   (Germany)

^o UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^p UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^q Data Reduction LLC   (United States)

^r New Zealand Cancer Control Trust   (New Zealand)

^s DUNEDIN HOSPITAL   (New Zealand)

^t CHRISTCHURCH HOSPITAL   (New Zealand)

^u PALMERSTON NORTH HOSPITAL   (New Zealand)

^v ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^w UNIVERSITY CLINIC OF NAVARRA   (Spain)

^x SHEBA MEDICAL CENTER   (Israel)

^y SHAARE ZEDEK MEDICAL CENTER   (Israel)

^z Hopital de Jour   (France)

^aa HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DIURETIC AGENT; FLUOROURACIL; FOLINIC ACID; LOW MOLECULAR WEIGHT HEPARIN; MICROSPHERE; OXALIPLATIN; RESIN; YTTRIUM 90; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEPATITIS; HUMAN; INTERMETHOD COMPARISON; LIVER; LIVER FAILURE; LIVER RESECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION HEPATITIS; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK ASSESSMENT; SELECTIVE INTERNAL RADIATION THERAPY; SPLENOMEGALY; STOMACH ULCER; THROMBOCYTOPENIA; VOMITING; BRACHYTHERAPY; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 84969513763     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.66.1181     Document Type: Article

References (35)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. Berber E, Pelley R, Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: A prospective study. J Clin Oncol 23:1358-1364, 2005
3. Navarra G, Ayav A, Weber JC, et al: Short- andlong term results of intraoperative radiofrequency ablation of liver metastases. Int J Colorectal Dis 20: 521-528, 2005
4. Rothbarth J, van de Velde CJ: Treatment of liver metastases of colorectal cancer. Ann Oncol 16 (Suppl 2):ii144-ii149, 2005 [Erratum Ann Oncol17: 727, 2006]
5. Van Cutsem E, Nordlinger B, Adam R, et al; European Colorectal Metastases Treatment Group: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212-2221, 2006
6. Abbas S, Lam V, Hollands M: Ten-year survival after liver resection for colorectal metastases: Systematic review and meta-analysis. ISRN Oncol 2011: 763245, 2011
7. Adam R: Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34(2, Suppl 1)S7-S11, 2007
8. Welch JP, Donaldson GA: The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 189:496-502, 1979
9. Helling TS, Martin M: Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol 21: 501-506, 2014
10. Kennedy A, Nag S, Salem R, et al: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13-23, 2007
11. Sangro B, Inarrairaegui M: Radioembolization for hepatocellular carcinoma: Evidence-based answers to frequently asked questions. J Nucl Med Radiat Ther 2:1000110, 2011
12. Gulec SA, Pennington K, Hall M, et al: Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: A novel approach to improving the safety of major hepatic resections. World J Surg Oncol 7:6, 2009
13. Ricke J, Bulla K, Kolligs F, et al; SORAMIC study group: Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC. Liver Int 35:620-626, 2015
14. Van Hazel G, Blackwell A, Anderson J, et al: Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78-85, 2004
15. Sharma RA, Van Hazel GA, Morgan B, et al: Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25:1099-1106, 2007
16. Gibbs P, Gebski V, Van Buskirk M, et al; SIRFLOX Study Group: Selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIRFLOX study. BMC Cancer 14:897, 2014
17. Sharma RA, Wasan HS, Love SB, et al; FOXFIRE Trial Management Group: FOXFIRE: A phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. Clin Oncol (R Coll Radiol) 20: 261-263, 2008
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
20. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy inmetastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26: 2013-2019, 2008
21. Gray B, Van Hazel G, Hope M, et al: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711-1720, 2001
22. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
23. Stubbs RS, Wickremesekera SK: Selective internal radiation therapy (SIRT): A new modality for treating patients with colorectal liver metastases. HPB (Oxford) 6:133-139, 2004
24. van Hazel GA, Pavlakis N, Goldstein D, et al: Treatment of fluorouracil-refractory patientswith liver metastases from colorectal cancer by using yttrium- 90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27:4089-4095, 2009
25. Faron M, Pignon JP, Malka D, et al: Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer 51:166-176, 2015
26. Ruers T, Punt CJA, Van Coevorden F, et al: Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 33:A3501, 2015
27. Saltz LB, Cox JV, Blanke C, et al; Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
28. Falcone A, Ricci S, Brunetti I, et al; Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007
29. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
30. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
31. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034, 2013
32. Van Cutsem E, Lenz HJ, Köhne CH, et al: Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33:692-700, 2015
33. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005
34. Tournigand C, AndréT, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
35. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 26: 3523-3529, 2008